FDA approved March 26, 2019

TRILURON is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy, and to simple analgesics, e.g., acetaminophen.

Permanent J Code

J7332

Important Safety Information

TRILURON is contraindicated in patients with known hypersensitivity to hyaluronate preparations or patients with infections/skin diseases in the area of the injection site/joint. The safety and effectiveness of TRILURON have not been established in pregnant women, nursing mothers, children, use in other joints, or concomitantly with other intra-articular (IA) injections. The effectiveness of a single treatment cycle of less than 3 injections has not been established.

Anaphylactoid and allergic reactions have been reported with this product. Transient increases in inflammation in the injected knee following TRILURON injection in some patients with inflammatory arthritis. Common adverse events include joint effusion/swelling/pain, injection site pain/hematoma, local skin reactions (rash, ecchymosis) and injection site warmth. Usually, local adverse events are transient and disappear spontaneously within a few days of resting the affected joint and/or applying ice locally. See package insert for full warnings, precautions and adverse events for more detail.

Rx Only.

Please see Full Prescribing Information.

Receive information and news about TRILURON from Fidia.

Reimbursement Support